Genetic testing of LRRK2 in Parkinson's disease: Is there a clinical role?

Parkinsonism and Related Disorders

Volumn 20, Issue SUPPL.1, 2014, Pages

  Buhat, Donna Mae Lyn ^a   Tan, Eng King ^a  

^a National Neuroscience Institute   (Singapore)

Author keywords

Genetic testing; LRRK2; Parkinson's disease

Indexed keywords

LEUCINE RICH REPEAT KINASE 2;

ARTICLE; AWARENESS; CLINICAL EFFECTIVENESS; DIAGNOSTIC VALUE; GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC SCREENING; HIGH RISK POPULATION; HUMAN; LRRK2 GENE; MEDICAL SERVICE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT ATTITUDE; PENETRANCE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROFESSIONAL COMPETENCE; PROFESSIONAL KNOWLEDGE; RELIABILITY; RISK ASSESSMENT; RISK FACTOR;

GENETIC TESTING; LRRK2; PARKINSON'S DISEASE;

GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES;

EID: 84887875465     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/S1353-8020(13)70015-4     Document Type: Article

References (19)

1. Foo JN, Liu J, Tan EK Next-generation sequencing diagnostics for neurological diseases/disorders: from clinical perspective. Hum Genet 2013, 132(7):721-734.
2. Tan EK, Skipper LM Pathogenic mutations in Parkinson disease. Hum Mutat 2007, 28(7):641-653.
3. Puschmann A Monogenic Parkinson's disease and parkinsonism: Clinical phenotypes and frequencies of known mutations. Parkinsonism Relat Disord 2013, 19(4):407-415.
4. Bonifati V Autosomal recessive parkinsonism. Parkinsonism Relat Disord 2012, 18(Suppl 1):S4-S6.
5. Peeraully T, Tan EK Genetic variants in sporadic Parkinson's disease: East vs West. Parkinsonism Relat Disord 2012, 18(Suppl 1):S63-S65.
6. Nichols WC, Pankratz N, Hernandez D, Paisán-Ruíz C, Jain S, Halter CA, Parkinson Study Group-PROGENI investigators, et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 2005, 365(9457):410-412.
7. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, International LRRK2 Consortium, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008, 7(7):583-590.
8. Farrer MJ, Stone JT, Lin CH, Dächsel JC, Hulihan MM, Haugarvoll K, et al. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism Relat Disord 2007, 13(2):89-92.
9. Ross OA, Wu YR, Lee MC, Funayama M, Chen ML, Soto AI, et al. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann Neurol 2008, 64(1):88-92.
10. Tan EK Identification of a common genetic risk variant (LRRK2 Gly2385Arg) in Parkinson's disease. Ann Acad Med Singapore 2006, 35(11):840-842.
11. Harbo HF, Finsterer J, Baets J, Van Broeckhoven C, Di Donato S, Fontaine B, et al. EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington's disease, Parkinson's disease and dystonias. Eur J Neurol 2009, 16(7):777-785.
12. Simon-Sanchez J, Marti-Masso JF, Sanchez-Mut JV, Paisan-Ruiz C, Martinez-Gil A, Ruiz-Martinez J, et al. Parkinson's disease due to the R1441G mutation in Dardarin: A founder effect in the Basques. Mov Disord 2006, 21:1954-1959.
13. Gorostidi A, Ruiz-Martinez J, Lopez de Munain A, Alzualde A, Masso JF LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity. Neurogenetics 2009, 10:157-159.
14. Shkedi-Rafid S, Ofer-Bialer G, Meiner V, Calderon-Margalit R Clinicians' attitudes toward general screening of the Ashkenazi-Jewish population for prevalent founder BRCA1/2 and LRRK2 mutations. Public Health Genomics 2013, 16(4):174-183.
15. Giladi N, Mirelman A, Thaler A, Bar-Shira A, Gurevich T, Orr-Urtreger A Fighting the risk of developing Parkinson's disease; clinical counseling for first degree relatives of patients with Parkinson's disease. J Neurol Sci 2011, 310:17-20.
16. Falcone DC, Wood EM, Xie SX, Siderowf A, Van Deerlin VM Genetic testing and Parkinson disease: assessment of patient knowledge, attitudes, and interest. J Genet Couns 2011, 20(4):384-395.
17. McDaniel SH The psychotherapy of genetics. Family Process 2005, 44(1):25-44.
18. Tan EK, Lee J, Hunter C, Shinawi L, Fook-Chong S, Jankovic J Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population. J Neurol Sci 2007, 252:113-120.
19. Dandara C, Greenberg J, Lambie L, Lombard Z, Naicker T, Ramesar R, et al. Direct-to-consumer genetic testing: To test or not to test, that is the question. S Afr Med J 2013, 103(8):510-512.